Nirav Raval
Cardiovascular Disease · Orlando, FLNPI 1962401331
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Cvrx, Inc. at 56.7% of the total. Reporting peaked in 2023 at $49,456 and has fallen 52.2% since, to $23,641 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 305 payments — averaging $578.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$100K
- Impulse Dynamics (USA) Inc.$63K
- Abbott$7K
- Medtronic$4K
- Abiomed$971
- United Therapeutics Corporation$258
- plus $1K from 16 others
Across 48 payments — averaging $8682.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$245K
- Procyrion, Inc.$100K
- Abbott$58K
- Impulse Dynamics (USA) Inc.$12K
- Actelion Pharmaceuticals, Ltd$2K
What the payments were for
- Consulting fees$103,77759%
- Speaking & faculty fees$45,80026%
- Travel & lodging$13,6308%
- Food & beverage$12,9607%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 147 | $99,906 |
| Impulse Dynamics (USA) Inc. | 62 | $62,852 |
| Abbott | 41 | $7,158 |
| Medtronic(2 entities) | 18 | $4,142 |
| Abiomed | 13 | $971 |
| United Therapeutics Corporation | 3 | $258 |
| Boston Scientific | 1 | $191 |
| Nuwellis, Inc. | 1 | $150 |
| Procyrion, Inc. | 1 | $141 |
| AstraZeneca | 1 | $122 |
| Pfizer | 3 | $81 |
| Merck | 2 | $54 |
| Scpharmaceuticals Inc. | 2 | $46 |
| Boehringer Ingelheim | 2 | $44 |
| Bridgebio Pharma, Inc. | 1 | $31 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Amgen | 1 | $21 |
| Bayer | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$97,795
- OPTIMIZER$89,534
- OPTIMIZER SMART SYSTEM$13,917
- CardioMEMS HF System$2,808
- HeartMate 3 Left Ventricular Dev$2,639
- HeartWare HVAD$2,610
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$579
- Impella$238
- Farapulse$191
- CARDIOMEMS$169
- COBALT DR MRI SURESCAN$159
- AQUADEX SMARTFLOW CONSOLE$150
- AORTIX SYSTEM$141
- REMODULIN$134
- TYVASO$134
- NONE$134
- HeartMate$124
- WAINUA$122
- AURORA EV-ICD MRI SURESCAN$113
How this compares
$176,292 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 14 | $8,616 |
| Tacrolimus | 26 | $2,811 |
| Rosuvastatin Calcium | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $44 | $8,61614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Orlando
- Rohit BhathejaOrlando$257K
- James TarverOrlando$112K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.